Literature DB >> 20571535

Pharmacotherapy: Valvulopathy in patients treated for hyperprolactinemia?

Steven Droogmans, Guy Van Camp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20571535     DOI： 10.1038/nrendo.2010.90

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  10 in total

1.  Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease.

Authors:  Guy Van Camp; Anja Flamez; Bernard Cosyns; Caroline Weytjens; Luc Muyldermans; Michel Van Zandijcke; Johan De Sutter; Patrick Santens; Pierre Decoodt; Christian Moerman; Danny Schoors
Journal:  Lancet       Date:  2004-04-10       Impact factor: 79.321

2.  Dopamine agonists and the risk of cardiac-valve regurgitation.

Authors:  René Schade; Frank Andersohn; Samy Suissa; Wilhelm Haverkamp; Edeltraut Garbe
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

3.  Valvular heart disease and the use of dopamine agonists for Parkinson's disease.

Authors:  Renzo Zanettini; Angelo Antonini; Gemma Gatto; Rosa Gentile; Silvana Tesei; Gianni Pezzoli
Journal:  N Engl J Med       Date:  2007-01-04       Impact factor: 91.245

4.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study)

Authors:  J P Singh; J C Evans; D Levy; M G Larson; L A Freed; D L Fuller; B Lehman; E J Benjamin
Journal:  Am J Cardiol       Date:  1999-03-15       Impact factor: 2.778

Review 5.  Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.

Authors:  Elena Valassi; Anne Klibanski; Beverly M K Biller
Journal:  J Clin Endocrinol Metab       Date:  2010-02-03       Impact factor: 5.958

6.  Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease.

Authors:  Ammar Wakil; Alan S Rigby; Andrew L Clark; Anna Kallvikbacka-Bennett; Stephen L Atkin
Journal:  Eur J Endocrinol       Date:  2008-07-14       Impact factor: 6.664

Review 7.  Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.

Authors:  M Kars; A M Pereira; J J Bax; J A Romijn
Journal:  Eur J Endocrinol       Date:  2008-08-14       Impact factor: 6.664

8.  Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.

Authors:  Annamaria Colao; Maurizio Galderisi; Antonella Di Sarno; Moira Pardo; Maria Gaccione; Marianna D'Andrea; Ermelinda Guerra; Rosario Pivonello; Giuseppe Lerro; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2008-08-05       Impact factor: 5.958

9.  Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline.

Authors:  M Lafeber; A M E Stades; G D Valk; M J Cramer; F Teding van Berkhout; P M J Zelissen
Journal:  Eur J Endocrinol       Date:  2010-01-13       Impact factor: 6.664

10.  Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.

Authors:  Marleen Kars; Victoria Delgado; Eduard R Holman; Richard A Feelders; Johannes W A Smit; Johannes A Romijn; Jeroen J Bax; Alberto M Pereira
Journal:  J Clin Endocrinol Metab       Date:  2008-06-17       Impact factor: 5.958
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.